These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22831177)

  • 21. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RANK ligand inhibition with denosumab for the management of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
    Tokuyama N; Tanaka S
    Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
    Maldonado-Gonzales E; Pietschmann P
    Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab, a rank ligand inhibitor for prevention of skeletal-related events due to bone metastases from solid tumors in adults.
    Wilkes GM
    Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):46-7. PubMed ID: 25391208
    [No Abstract]   [Full Text] [Related]  

  • 29. RANKL, denosumab, and giant cell tumor of bone.
    Thomas DM
    Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
    Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
    J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.
    Hofbauer LC; Zeitz U; Schoppet M; Skalicky M; Schüler C; Stolina M; Kostenuik PJ; Erben RG
    Arthritis Rheum; 2009 May; 60(5):1427-37. PubMed ID: 19404943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
    Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab: in cancer treatment-induced bone loss.
    Muir VJ; Scott LJ
    BioDrugs; 2010 Dec; 24(6):379-86. PubMed ID: 21043545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.
    Candelaria-Quintana D; Dayao ZR; Royce ME
    Breast Cancer Res Treat; 2012 Apr; 132(2):355-63. PubMed ID: 21987034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients.
    Yee AJ; Raje NS
    Clin Interv Aging; 2012; 7():331-8. PubMed ID: 22977302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.